Bimekizumab
As of the edition of 20 October 2026, Bimekizumab is an antibody: marketed, first approved in 2021 (EU); acts on IL17A and IL17F; US protection ends in 2035.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2023
- Kind
- Antibody
- Brand name
- Bimzelx
- First approved
- 20 August 2021 (EU)
- Approvals on record
- 9 in 3 regions
- Holder of the most recent approval
- UCB; 3 holders in all
- Registered trials
- 55, 2 stopped early
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Infections; Immune system; Heart and blood vessels; Inherited and neonatal
US protection
US protection ends in 2035.
US protection ends in 2035, computed as 12 years from the first US licence because FDA publishes no date for this product. The application that gives this date is held by UCB. The date is computed, not published.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
Companies that need a new molecule because of this drug
2 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Bimekizumab.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 8 | 6 | 1 | 1 |
| Phase 2 | 16 | 12 | 4 | 0 |
| Phase 3 | 25 | 19 | 6 | 0 |
| Phase 4 | 5 | 2 | 2 | 1 |
| All trials | 55 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| UCB | Applicant and Lead sponsor of trials | 2012 to now |